Yinzhu Pharmaceuticals (银珠医药) is primarily engaged in research and development of anti-tumor new drugs and holds independent intellectual property. Its core product is the national Class 1.1 anti-tumor drug 苏恩·羧胺三唑胶丸, an original chemical new drug that acts on the TNF-α target. The drug is used for treating advanced non-small cell lung cancer and has completed Phase III clinical trials. The company’s candidate is described as the world’s first immunotherapy based on tumor inflammatory microenvironment research to complete clinical validation and the first in China to conduct clinical trials for stage IV metastatic lung cancer. Public reporting notes that the company recently closed financing, reflecting external investor interest in its clinical-stage program. No operating metrics such as revenue or user counts were disclosed in the article.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2020